| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMAM | Ordinary Shares | Purchase | $38.1M | +3.38M | +5.44% | $11.27 | 65.5M | Apr 18, 2023 | See Footnotes | F1, F2, F3 |
| transaction | AMAM | Ordinary Shares | Purchase | $10.6M | +952K | +1.45% | $11.15 | 66.4M | Apr 19, 2023 | See Footnotes | F2, F4, F5 |
| transaction | AMAM | Ordinary Shares | Purchase | $10.3M | +887K | +1.33% | $11.60 | 67.3M | Apr 20, 2023 | See Footnotes | F2, F6, F7 |
| Id | Content |
|---|---|
| F1 | Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $10.73 to $11.45 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III (as defined below). |
| F2 | Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. |
| F3 | Represents (i) 49,771,365 ordinary shares beneficially owned by the Master Fund and (ii) 15,703,177 ordinary shares beneficially owned by Fund III. |
| F4 | Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $10.87 to $11.50 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commissioner, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III. |
| F5 | Represents (i) 49,771,365 ordinary shares beneficially owned by the Master Fund and (ii) 16,655,086 ordinary shares beneficially owned by Fund III. |
| F6 | Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $11.45 to $11.65 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commissioner, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III. |
| F7 | Represents (i) 49,771,365 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III. |